Peter Guzzo
Corporate Officer/Principal presso TRYPTAMINE THERAPEUTICS LIMITED
Profilo
Peter Guzzo is the founder of ConSynance Therapeutics, Inc. which was founded in 2015.
He was the Chief Executive Officer of the company.
Currently, he is the Vice President-Drug Development at Tryp Therapeutics, Inc. where he started working in 2020.
Previously, he worked as the Director-Drug Discovery at Curia Global, Inc. from 1996 to 2015.
Dr. Guzzo holds a doctorate degree from the University of Notre Dame and an undergraduate degree from Assumption College.
Posizioni attive di Peter Guzzo
| Società | Posizione | Inizio |
|---|---|---|
| TRYPTAMINE THERAPEUTICS LIMITED | Corporate Officer/Principal | 22/12/2020 |
Precedenti posizioni note di Peter Guzzo
| Società | Posizione | Fine |
|---|---|---|
| ALBANY MOLECULAR RESEARCH, INC. | Corporate Officer/Principal | 01/01/2015 |
ConSynance Therapeutics, Inc.
 ConSynance Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology ConSynance Therapeutics, Inc. is an American clinical-stage rare CNS disease company that focuses on Prader-Willi Syndrome (PWS). PWS is a rare genetic disorder that affects approximately 1 in 15,000 people and has no adequate treatment. The hallmark symptom of PWS is an insatiable appetite that causes obesity. The private company was founded by Peter Guzzo, and their focus is on developing treatments for PWS by addressing the dysfunction of the hypothalamus, a small endocrine organ at the base of the brain that plays a crucial role in many bodily functions. | Amministratore Delegato | - |
Formazione di Peter Guzzo
| University of Notre Dame | Doctorate Degree |
| Assumption College | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 3 |
|---|---|
Curia Global, Inc.
 Curia Global, Inc. Miscellaneous Commercial ServicesCommercial Services Curia Global, Inc. engages in drug research and development, and manufacturing. It offers drug delivery, drug development, analytical services, API development and manufacturing, and drug product solutions. The company was founded by Thomas E. D'Ambra on June 19, 1991 and is headquartered in Albany, NY. | Commercial Services |
Tryp Therapeutics, Inc.
 Tryp Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Tryp Therapeutics, Inc. is a pharmaceutical company, which engages in identifying and developing clinical-stage compounds for orphan diseases and other diseases with high unmet medical needs. The company was founded on September 24, 2019 and is headquartered in Kelowna, Canada. | Health Technology |
ConSynance Therapeutics, Inc.
ConSynance Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology ConSynance Therapeutics, Inc. is an American clinical-stage rare CNS disease company that focuses on Prader-Willi Syndrome (PWS). PWS is a rare genetic disorder that affects approximately 1 in 15,000 people and has no adequate treatment. The hallmark symptom of PWS is an insatiable appetite that causes obesity. The private company was founded by Peter Guzzo, and their focus is on developing treatments for PWS by addressing the dysfunction of the hypothalamus, a small endocrine organ at the base of the brain that plays a crucial role in many bodily functions. | Health Technology |
- Borsa valori
- Insiders
- Peter Guzzo
